← Back to patent-cliff list
Mycophenolate mofetil oral (Azurity Pharmaceuticals)
Tier C — Watch / tradeMycophenolate mofetil oral (Azurity Pharmaceuticals)
Azurity Pharmaceuticals Inc
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：IMPDH
Brand：Myhibbin
Indications (approved)：Liver transplant rejection, Kidney transplant rejection
Regional status
US
Approved
2024-05-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Mycophenolate mofetil oral (Azurity Pharmaceuticals)?
Approved indications include: Liver transplant rejection, Kidney transplant rejection.
When does the Mycophenolate mofetil oral (Azurity Pharmaceuticals) patent expire?
No public expiry year is available for Mycophenolate mofetil oral (Azurity Pharmaceuticals) yet; this page updates once verified.
How do I get a quote for Mycophenolate mofetil oral (Azurity Pharmaceuticals) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27